Literature DB >> 22560712

A radiosensitizing effect of artesunate in glioblastoma cells is associated with a diminished expression of the inhibitor of apoptosis protein survivin.

Sebastian Reichert1, Vera Reinboldt, Stephanie Hehlgans, Thomas Efferth, Claus Rödel, Franz Rödel.   

Abstract

BACKGROUND AND
PURPOSE: Novel strategies to overcome an irradiation resistant phenotype may help to increase therapeutic efficacy in glioblastoma multiforme. The present study aimed to elucidate radiation sensitizing properties of artesunate, a semi synthetic derivate of artemisinin and to assess factors involved in this effect.
MATERIALS AND METHODS: LN229 and U87MG cells were treated with various concentrations of artesunate and radiation response was determined by a colony forming assay. Cell numbers, apoptosis induction, cell cycle distribution, and DNA repair following combined modality treatment were monitored by MTT-, caspase 3/7 assay, cytofluorometry, and γ-H2AX foci formation. Expression of survivin, survivin-GFP fusion protein, XIAP, cellular (c)IAP1 and cIAP2 was monitored by Western immunoblotting.
RESULTS: Treatment of glioma cells with artesunate and irradiation resulted in an increased apoptotic fraction, pronounced G2/M arrest and increased DNA damage as demonstrated by an elevated amount of γ-H2AX foci/nucleus. Incubation with artesunate lowers survivin expression in a time and dose-dependent manner, whereas expression of XIAP, cIAP1 and cIAP2 was not affected. In clonogenic assays, treatment with artesunate revealed a significantly reduced surviving fraction, whereas stable over expression of a survivin-GFP protein reversed artesunate-mediated radiosensitization.
CONCLUSION: Artesunate selectively down regulates survivin that contributes to a radio-sensitization of glioma cells by an increased induction of apoptosis, cell cycle arrest, and a hampered DNA damage response.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22560712     DOI: 10.1016/j.radonc.2012.03.018

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  16 in total

1.  Artesunate and its emerging anti-neoplastic effects: beyond its role in attenuating tumor growth in osteosarcomas.

Authors:  Shailendra Kapoor
Journal:  J Zhejiang Univ Sci B       Date:  2012-12       Impact factor: 3.066

Review 2.  The multifaceted NF-kB: are there still prospects of its inhibition for clinical intervention in pediatric central nervous system tumors?

Authors:  Mariana Medeiros; Marina Ferreira Candido; Elvis Terci Valera; María Sol Brassesco
Journal:  Cell Mol Life Sci       Date:  2021-07-31       Impact factor: 9.261

3.  BUB1 and BUBR1 inhibition decreases proliferation and colony formation, and enhances radiation sensitivity in pediatric glioblastoma cells.

Authors:  Andressa Gois Morales; Julia Alejandra Pezuk; María Sol Brassesco; Jaqueline Carvalho de Oliveira; Rosane Gomes de Paula Queiroz; Hélio Rubens Machado; Carlos Gilberto Carlotti; Luciano Neder; Harley Francisco de Oliveira; Carlos Alberto Scrideli; Luiz Gonzaga Tone
Journal:  Childs Nerv Syst       Date:  2013-06-02       Impact factor: 1.475

4.  Artesunate suppresses tumor growth and induces apoptosis through the modulation of multiple oncogenic cascades in a chronic myeloid leukemia xenograft mouse model.

Authors:  Chulwon Kim; Jong Hyun Lee; Sung-Hoon Kim; Gautam Sethi; Kwang Seok Ahn
Journal:  Oncotarget       Date:  2015-02-28

5.  Survivin-targeting Artificial MicroRNAs Mediated by Adenovirus Suppress Tumor Activity in Cancer Cells and Xenograft Models.

Authors:  Yudan Chi; Xiang Wang; Yong Yang; Chao Zhang; Hildegund C J Ertl; Dongming Zhou
Journal:  Mol Ther Nucleic Acids       Date:  2014-11-04       Impact factor: 10.183

6.  Treatment of Iron-Loaded Veterinary Sarcoma by Artemisia annua.

Authors:  Elmar Breuer; Thomas Efferth
Journal:  Nat Prod Bioprospect       Date:  2014-04-12

Review 7.  A conceptually new treatment approach for relapsed glioblastoma: coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma Care.

Authors:  Richard E Kast; John A Boockvar; Ansgar Brüning; Francesco Cappello; Wen-Wei Chang; Boris Cvek; Q Ping Dou; Alfonso Duenas-Gonzalez; Thomas Efferth; Daniele Focosi; Seyed H Ghaffari; Georg Karpel-Massler; Kirsi Ketola; Alireza Khoshnevisan; Daniel Keizman; Nicolas Magné; Christine Marosi; Kerrie McDonald; Miguel Muñoz; Ameya Paranjpe; Mohammad H Pourgholami; Iacopo Sardi; Avishay Sella; Kalkunte S Srivenugopal; Marco Tuccori; Weiguang Wang; Christian R Wirtz; Marc-Eric Halatsch
Journal:  Oncotarget       Date:  2013-04

8.  Artemisinin derivative artesunate induces radiosensitivity in cervical cancer cells in vitro and in vivo.

Authors:  Judong Luo; Wei Zhu; Yiting Tang; Han Cao; Yuanyuan Zhou; Rong Ji; Xifa Zhou; Zhongkai Lu; Hongying Yang; Shuyu Zhang; Jianping Cao
Journal:  Radiat Oncol       Date:  2014-03-25       Impact factor: 3.481

9.  CUSP9* treatment protocol for recurrent glioblastoma: aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, sertraline augmenting continuous low dose temozolomide.

Authors:  Richard E Kast; Georg Karpel-Massler; Marc-Eric Halatsch
Journal:  Oncotarget       Date:  2014-09-30

10.  Ultra-short laser-accelerated proton pulses have similar DNA-damaging effectiveness but produce less immediate nitroxidative stress than conventional proton beams.

Authors:  S Raschke; S Spickermann; T Toncian; M Swantusch; J Boeker; U Giesen; G Iliakis; O Willi; F Boege
Journal:  Sci Rep       Date:  2016-08-31       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.